Lucidarax Daraxonrasib 150mg Tablets 30's

Daraxonrasib, also known as RMC-6236, is a targeted cancer medicine that inhibits RAS signalling. RAS proteins can drive cancer cell growth and survival when abnormally activated. By inhibiting RAS activity, daraxonrasib helps interfere with pathways involved in tumour growth.

Daraxonrasib is an oral targeted anticancer medicine. The US FDA approved it for certain adults with metastatic pancreatic adenocarcinoma. The usual recommended dose is 300 mg once daily, so a 100 mg tablet is a strength of the medicine, not necessarily the patient's total daily dose.

It is available as an oral tablet. Treatment should be initiated and monitored by an oncologist experienced in cancer-directed therapy.

• Daraxonrasib is approved in the United States for adults with metastatic pancreatic adenocarcinoma who have received at least one previous systemic treatment or who are not candidates for multi-agent systemic therapy.

• Daraxonrasib is also being investigated in clinical trials for other RAS-related cancers, including certain lung cancers and other solid tumours. These investigational uses should not be confused with the approved indication.

• Targeted RAS inhibition: Interferes with RAS-driven signalling involved in cancer growth.
• Tumour control: May slow tumour progression in eligible patients.
• Treatment response: Clinical-trial results in previously treated metastatic pancreatic cancer showed improved overall survival, progression-free survival and response rates compared with the study's standard-care chemotherapy options. Individual outcomes vary.

• Take orally once daily, at approximately the same time each day.
• The US-approved recommended dose is 300 mg once daily; this may correspond to three 100 mg tablets. The treating oncologist must confirm the prescribed regimen.
• Swallow tablets whole; do not crush, split or chew them.
• It may be taken with or without food.
• If a dose is missed by more than four hours, skip it and take the next dose at the regular time.
• If vomiting occurs after taking a dose, do not take an extra dose; resume at the next scheduled time.
• Treatment generally continues until disease progression or unacceptable toxicity, subject to the oncologist's assessment.

Common:

• Reported common adverse reactions include the following:
• Skin rash and itching
• Diarrhoea
• Mouth sores or inflammation of the mouth (stomatitis)
• Nausea and vomiting
• Fatigue
• Abdominal pain
• Reduced appetite
• Swelling (oedema)
• Bleeding events

The severity varies between patients.

Serious:

Seek urgent medical assessment if any of the following occur:

• Severe skin reactions: Extensive rash, painful skin, skin cracking, blistering or signs of infection.
• Severe diarrhoea or dehydration: Persistent diarrhoea, dizziness, reduced urine output or inability to keep fluids down.
• Gastrointestinal perforation: Severe or sudden abdominal pain, a rigid abdomen, fever or collapse.
• Lung inflammation (interstitial lung disease/pneumonitis): New or worsening breathlessness, persistent cough, chest discomfort or fever.
• Serious infection or bleeding: Fever with marked weakness, unusual bleeding, black stools or blood in vomit.

Daraxonrasib carries warnings for dermatologic toxicity, diarrhoea, gastrointestinal perforation, interstitial lung disease/pneumonitis and harm to an unborn baby. New or worsening symptoms should be reported promptly.

Daraxonrasib is affected by the CYP3A enzyme and the P-glycoprotein (P-gp) transport system. Certain medicines may increase its blood levels and toxicity, while others may reduce its effectiveness.

• Strong CYP3A inhibitors: Some combinations must be avoided; others require a dose reduction.
• Moderate CYP3A inhibitors: May require a dose adjustment.
• P-gp inhibitors: May increase daraxonrasib exposure and require dose adjustment.
• CYP3A inducers: May reduce drug exposure; strong inducers should generally be avoided.
• Cyclosporine A: Avoid concomitant systemic use.
• P-gp substrate medicines: May need to be administered at least four hours apart.

Tell the oncologist about all prescription medicines, over-the-counter products, vitamins and herbal supplements. Never adjust Daraxonrasib's dose yourself to manage an interaction.

• Store according to the temperature and conditions stated on the product packaging and official prescribing information.
• Keep the tablets in their original packaging as directed.
• Protect from moisture and keep out of reach of children.
• Do not use tablets that are damaged, discoloured or past their expiry date.

• Use only under the supervision of a qualified medical oncologist.
• Before treatment, review the diagnosis, prior therapies, current medicines and relevant laboratory results.
• Follow the prescribed skin-care plan. The US prescribing information recommends moisturising creams, a topical corticosteroid on the face and chest, sun protection with broad-spectrum SPF 30 or higher, and consideration of preventive oral antibiotics where appropriate. These measures should be clinician-directed.
• Maintain adequate fluid intake, particularly if diarrhoea or vomiting develops.
• Report new cough, breathlessness, severe abdominal pain, persistent diarrhoea or a significant rash immediately.
• Do not stop, restart or reduce treatment without discussing it with the oncology team.